CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 12, 2022--

CANbridge Pharmaceuticals, Inc. (HKEX:1228) , a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, today announced that it will be participating in two upcoming investor conferences.

• Morgan Stanley 20th Annual Global Healthcare Conference (New York)
  • CEO, James Xue, PhD, to participate in a fireside chat on Wednesday, September 14, 2022 at 4:05 PM EST
• J.P. Morgan Global Healthcare Shanghai Conference (Shanghai)
  • September 26- 27

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. (HKEX:1228) is a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 10 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. CANbridge is also building next-generation gene therapy development capability through a combination of collaboration with world-leading researchers and biotech companies and internal capacity. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the UMass Chan Medical School, the University of Washington School of Medicine, Scriptr Global and LogicBio.

For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the data on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

View source version on businesswire.com:https://www.businesswire.com/news/home/20220912005900/en/

CONTACT: U.S. Investor Relations:

Chris Brinzey

ICR Westwicke

Chris.brinzey@westwicke.comChina Investor Relations

CANbridge Pharmaceuticals Inc.

ir@canbridgepharma.comMedia:

Deanne Eagle

Planet Communications

deanne@planetcommunications.nyc

917.837.5866

KEYWORD: MASSACHUSETTS CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC

INDUSTRY KEYWORD: ONCOLOGY HEALTH GENERAL HEALTH RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: CANbridge Pharmaceuticals, Inc.

Copyright Business Wire 2022.